Literature DB >> 8434001

Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus.

K D Bell1, O Ramilo, E S Vitetta.   

Abstract

Two different populations of infected T cells are present in human immunodeficiency virus (HIV)-infected individuals: activated cells that produce virions and quiescent cells that harbor the viral genome but are unable to produce virus unless they are activated. Using an in vitro model of acute HIV infection, we have evaluated the effect of depleting activated T cells with an immunotoxin and subsequently inhibiting activation of quiescent T cells with an immunosuppressive agent. CD25 (Tac, p55), the alpha chain of the interleukin 2 receptor, is expressed on activated, but not quiescent, T cells. An anti-CD25-ricin A chain immunotoxin eliminated activated, CD25+ HIV-infected cells and, thereby, inhibited viral production by these cells. Subsequent addition of cyclosporine to the residual CD25- cells prevented their activation and thereby suppressed their ability to produce virus and to propagate the infection to uninfected T cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8434001      PMCID: PMC45883          DOI: 10.1073/pnas.90.4.1411

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  HIV infection is blocked in vitro by recombinant soluble CD4.

Authors:  R A Fisher; J M Bertonis; W Meier; V A Johnson; D S Costopoulos; T Liu; R Tizard; B D Walker; M S Hirsch; R T Schooley
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

2.  A soluble CD4 protein selectively inhibits HIV replication and syncytium formation.

Authors:  R E Hussey; N E Richardson; M Kowalski; N R Brown; H C Chang; R F Siliciano; T Dorfman; B Walker; J Sodroski; E L Reinherz
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

3.  The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond.

Authors:  V Ghetie; P Thorpe; M A Ghetie; P Knowles; J W Uhr; E S Vitetta
Journal:  J Immunol Methods       Date:  1991-09-13       Impact factor: 2.303

4.  Genomic heterogeneity of AIDS retroviral isolates from North America and Zaire.

Authors:  S Benn; R Rutledge; T Folks; J Gold; L Baker; J McCormick; P Feorino; P Piot; T Quinn; M Martin
Journal:  Science       Date:  1985-11-22       Impact factor: 47.728

5.  Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia. Potential clinical importance.

Authors:  J P Allain; Y Laurian; D A Paul; F Verroust; M Leuther; C Gazengel; D Senn; M J Larrieu; C Bosser
Journal:  N Engl J Med       Date:  1987-10-29       Impact factor: 91.245

6.  Treatment of premalignancy: prevention of lymphoma in radiation leukemia virus-inoculated mice by cyclosporin A and immunotoxin.

Authors:  E Yefenof; G Abboud; S Epszteyn; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

7.  Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen.

Authors:  D H Smith; R A Byrn; S A Marsters; T Gregory; J E Groopman; D J Capon
Journal:  Science       Date:  1987-12-18       Impact factor: 47.728

8.  New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.

Authors:  P E Thorpe; P M Wallace; P P Knowles; M G Relf; A N Brown; G J Watson; R E Knyba; E J Wawrzynczak; D C Blakey
Journal:  Cancer Res       Date:  1987-11-15       Impact factor: 12.701

Review 9.  The multichain interleukin-2 receptor: a target for immunotherapy.

Authors:  T A Waldmann; I H Pastan; O A Gansow; R P Junghans
Journal:  Ann Intern Med       Date:  1992-01-15       Impact factor: 51.598

10.  Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection.

Authors:  M I Bukrinsky; T L Stanwick; M P Dempsey; M Stevenson
Journal:  Science       Date:  1991-10-18       Impact factor: 63.714

View more
  10 in total

1.  The use of two immunosuppressive drugs, cyclosporin A and tacrolimus, to inhibit virus replication and apoptosis in cells infected with feline immunodeficiency virus.

Authors:  E Mortola; Y Endo; K Ohno; T Watari; H Tsujimoto; A Hasegawa
Journal:  Vet Res Commun       Date:  1998-12       Impact factor: 2.459

2.  A switch-on mechanism to activate maize ribosome-inactivating protein for targeting HIV-infected cells.

Authors:  Sue Ka-Yee Law; Rui-Rui Wang; Amanda Nga-Sze Mak; Kam-Bo Wong; Yong-Tang Zheng; Pang-Chui Shaw
Journal:  Nucleic Acids Res       Date:  2010-06-17       Impact factor: 16.971

3.  Zidovudine, lamivudine, and abacavir have different effects on resting cells infected with human immunodeficiency virus in vitro.

Authors:  Jesús Saavedra-Lozano; Cynthia C McCoig; Yanying Cao; Ellen S Vitetta; Octavio Ramilo
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

4.  Pseudomonas exotoxin antisense RNA selectively kills hepatitis B virus infected cells.

Authors:  Peter Hafkemeyer; Ulrich Brinkmann; Elizabeth Brinkmann; Ira Pastan; Hubert-E Blum; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

5.  Inhibition of human immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A.

Authors:  S R Bartz; E Hohenwalter; M K Hu; D H Rich; M Malkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

6.  Human immunodeficiency virus 1 reservoir in CD4+ T cells is restricted to certain V beta subsets.

Authors:  D Dobrescu; S Kabak; K Mehta; C H Suh; A Asch; P U Cameron; A S Hodtsev; D N Posnett
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

7.  Targeted cytotoxic therapy kills persisting HIV infected cells during ART.

Authors:  Paul W Denton; Julie M Long; Stephen W Wietgrefe; Craig Sykes; Rae Ann Spagnuolo; Olivia D Snyder; Katherine Perkey; Nancie M Archin; Shailesh K Choudhary; Kuo Yang; Michael G Hudgens; Ira Pastan; Ashley T Haase; Angela D Kashuba; Edward A Berger; David M Margolis; J Victor Garcia
Journal:  PLoS Pathog       Date:  2014-01-09       Impact factor: 6.823

Review 8.  Clinical targeting recombinant immunotoxins for cancer therapy.

Authors:  Meng Li; Zeng-Shan Liu; Xi-Lin Liu; Qi Hui; Shi-Ying Lu; Lin-Lin Qu; Yan-Song Li; Yu Zhou; Hong-Lin Ren; Pan Hu
Journal:  Onco Targets Ther       Date:  2017-07-20       Impact factor: 4.147

Review 9.  Antiviral Activity of Ribosome-Inactivating Proteins.

Authors:  Lucía Citores; Rosario Iglesias; José M Ferreras
Journal:  Toxins (Basel)       Date:  2021-01-22       Impact factor: 4.546

Review 10.  Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure.

Authors:  Jeffrey C Umotoy; Steven W de Taeye
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.